Liver Disease
News
WHO analysis: Cost of new HCV meds unaffordable globally
The cost of new medicines for patients with hepatitis C virus vary widely around the globe, especially when adjusted for national wealth, results...
News
Hepatitis Outlook: June 2016
From the AGA Journals
VIDEO: Nearly half of Medicaid patients denied antivirals for HCV
State Medicaid programs denied nearly half of requests to cover direct-acting antiviral drugs for patients with chronic hepatitis C virus...
From the AGA Journals
Early sustained viral response linked to better outcomes among HCV patients
Among patients with hepatitis C virus infection who were in compensated cirrhosis, sustained viral response was associated with significantly...
News
FDA approves Epclusa for patients with chronic hepatitis C
Adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease) can now be prescribed Epclusa. The...
News
Study identifies changing trends in PBC incidence, mortality
A new study has identified a higher mortality rate among males with primary biliary cholangitis (PBC) and a lower sex ratio in disease prevalence...
News
New HCV test approach could cut costs, streamline diagnosis
Key clinical point: The diagnostic rate of chronic hepatitis C virus may be increased by point of care hepatitis C virus core antigen assessment....
Conference Coverage
HCV patients had distinct mucosal microbiome
SAN DIEGO – Patients with hepatitis C virus infections had distinct duodenal mucosal microbiomes and greater intestinal permeability, compared...
News
HCV regimen found safe, effective in patients with severe renal disease
A 12-week regimen of ombitasvir, paritaprevir, ritonavir, and dasabuvir achieved sustained viral response for 90% of patients with genotype 1...
Conference Coverage
Race predicts poor outcomes in people with liver cancer
Race was the strongest predictor of outcome in patients with hepatocellular carcinoma.